Literature DB >> 34166845

Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review.

Theo Gülen1, Cem Akin2, Patrizia Bonadonna3, Frank Siebenhaar4, Sigurd Broesby-Olsen5, Knut Brockow6, Marek Niedoszytko7, Boguslaw Nedoszytko8, Hanneke N G Oude Elberink9, Joseph H Butterfield10, Wolfgang R Sperr11, Ivan Alvarez-Twose12, Hans-Peter Horny13, Karl Sotlar14, Juliana Schwaab3, Mohamad Jawhar15, Roberta Zanotti16, Gunnar Nilsson17, Jonathan J Lyons18, Melody C Carter18, Tracy I George19, Olivier Hermine20, Jason Gotlib21, Alberto Orfao22, Massimo Triggiani23, Andreas Reiter15, Karin Hartmann24, Mariana Castells25, Michel Arock26, Lawrence B Schwartz27, Dean D Metcalfe18, Peter Valent11.   

Abstract

In recent years, knowledge about mechanisms underlying mast cell activation (MCA) and accumulation in various pathologic conditions increased substantially. In addition, criteria and a classification of MCA syndromes (MCASs) have been set forth. MCAS is defined by typical clinical symptoms, a substantial increase in serum tryptase level during an attack over the patient's baseline tryptase, and a response of the symptoms to drugs targeting mast cells, mediator production, and/or mediator effects. Alternative diagnostic criteria of MCAS have also been suggested, but these alternative criteria often lack specificity and validation. In this report, we critically review the contemporary literature relating to MCAS and compare the specificity, sensitivity, and strength of MCAS-related parameters within proposals to diagnose and classify MCAS and its variants. Furthermore, we highlight the need to apply specific consensus criteria in the evaluation and classification of MCAS in individual patients. This is an urgent and important medical necessity because as an increasing number of patients are being given a misdiagnosis of MCAS based on nonspecific criteria, which contributes to confusion and frustration by patients and caregivers and sometimes may delay recognition and treatment of correct medical conditions that often turn out to be unrelated to MCA.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anaphylaxis; Hereditary alpha Tryptasemia; MCAS; Mast cells; Mastocytosis; Tryptase; Vienna consensus criteria

Mesh:

Substances:

Year:  2021        PMID: 34166845     DOI: 10.1016/j.jaip.2021.06.011

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  6 in total

1.  COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication.

Authors:  Tiago Azenha Rama; Joana Miranda; Diana Silva; Luís Amaral; Eunice Castro; Alice Coimbra; André Moreira; José Luís Plácido
Journal:  Vaccines (Basel)       Date:  2022-05-04

2.  Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders.

Authors:  Julien Rossignol; Amani Ouedrani; Cristina Bulai Livideanu; Stéphane Barete; Louis Terriou; David Launay; Richard Lemal; Celine Greco; Laurent Frenzel; Cecile Meni; Christine Bodemere-Skandalis; Laura Polivka; Anne-Florence Collange; Hassiba Hachichi; Sonia Bouzourine; Djazira Nait Messaoud; Mathilde Negretto; Laurence Vendrame; Marguerite Jambou; Marie Gousseff; Stéphane Durupt; Jean-Christophe Lega; Jean-Marc Durand; Caroline Gaudy; Gandhi Damaj; Marie-Pierre Gourin; Mohamed Hamidou; Laurence Bouillet; Edwige Le Mouel; Alexandre Maria; Patricia Zunic; Quentin Cabrera; Denis Vincent; Christian Lavigne; Etienne Riviere; Clement Gourguechon; Marie Courbebaisse; David Lebeaux; Béatrice Parfait; Gérard Friedlander; Anne Brignier; Ludovic Lhermitte; Thierry Jo Molina; Julie Bruneau; Julie Agopian; Patrice Dubreuil; Dana Ranta; Alexandre Mania; Michel Arock; Isabelle Staropoli; Olivier Tournilhac; Olivier Lortholary; Olivier Schwartz; Lucienne Chatenoud; Olivier Hermine
Journal:  J Allergy Clin Immunol Pract       Date:  2022-01-21

Review 3.  Mastocytosis and Mast Cell Activation Disorders: Clearing the Air.

Authors:  Clayton Webster Jackson; Cristina Marie Pratt; Chase Preston Rupprecht; Debendra Pattanaik; Guha Krishnaswamy
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

Review 4.  Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022.

Authors:  Peter Valent; Karin Hartmann; Patrizia Bonadonna; Marek Niedoszytko; Massimo Triggiani; Michel Arock; Knut Brockow
Journal:  Int Arch Allergy Immunol       Date:  2022-05-23       Impact factor: 3.767

Review 5.  Acute Urticaria and Anaphylaxis: Differences and Similarities in Clinical Management.

Authors:  Luis Felipe Ensina; Taek Ki Min; Mara Morelo Rocha Félix; Carolina Tavares de Alcântara; Célia Costa
Journal:  Front Allergy       Date:  2022-04-15

6.  Multi-phasic life-threatening anaphylaxis refractory to epinephrine managed by extracorporeal membrane oxygenation (ECMO): A case report.

Authors:  Juergen Grafeneder; Florian Ettl; Alexandra-Maria Warenits; Nina Buchtele; Elisabeth Lobmeyr; Thomas Staudinger; Michael Schwameis; Wolfgang R Sperr; Georg Gelbenegger; Christian Schoergenhofer; Bernd Jilma
Journal:  Front Allergy       Date:  2022-07-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.